Options: Hide MedDRA Preferred Terms
Information about indications was extracted from the indications and usage sections of the labels.
Indication | Labels | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Atrial fibrillation | x | x | x | x | x | x | x | x | x | x | x | x | x | ||||
Cardiac failure congestive | x | x | x | ||||||||||||||
Cerebral artery embolism | x | x | x | ||||||||||||||
Cerebrovascular accident | x | x | x | x | x | x | x | x | x | x | |||||||
Clotting | x | x | x | ||||||||||||||
Embolism | x | x | x | x | x | ||||||||||||
Genetic polymorphism | x | ||||||||||||||||
Haemorrhage | x | ||||||||||||||||
Hepatic function abnormal | x | ||||||||||||||||
Hepatic impairment | x | ||||||||||||||||
Increased anticoagulant effect | x | ||||||||||||||||
Myocardial infarction | x | x | x | x | x | x | x | x | x | x | x | ||||||
Pulmonary embolism | x | x | x | x | x | x | x | x | x | x | x | x | x | ||||
Renal failure | x | ||||||||||||||||
Renal impairment | x | ||||||||||||||||
Thromboembolic event | x | x | x | x | x | x | |||||||||||
Thromboembolism | x | ||||||||||||||||
Thrombophlebitis | x | x | x | ||||||||||||||
Thrombosis | x | ||||||||||||||||
Venous thrombosis | x | x | x | x | x | x | x | x | x | x | x | x | x |
standard – alternative
100% | ||
75% | ||
50% | ||
10% | ||
frequent (1% to 100%) | ||
infrequent (0.1% to 1%) | ||
rare (<0.1%) | ||
postmarketing | ||
0% | ||
no frequency information | ||
not found on label |